By Fineline Cube 
WuXi AppTec Co., Ltd. (SHA: 603259; HKG: 2359), China’s leading integrated Contract Research Organization (CRO), announced its financial results for the first quarter of 2026, reporting revenues of RMB 12.44 billion (USD 1.82 billion), representing a 28.8% year-over-year increase.
Financial Performance Summary
| Metric | Q1 2026 Result | YoY Change | Notes |
|---|---|---|---|
| Total Revenue | RMB 12.44B (USD 1.82B) | +28.8% | Strong across all segments |
| Revenue from Continuing Operations | Not specified separately | +39.4% | Core business acceleration |
| Total Profit | RMB 5.6B (USD 819M) | +31.01% | Robust profitability |
| Backlog (Continuing Operations) | RMB 59.77B (USD 8.75B) | +23.6% | As of March 31, 2026 |
Business Segment Performance
Chemistry Business (Primary Growth Driver)
- Revenue: RMB 10.62 billion (USD 1.55 billion)
- YoY Growth: +43.7%
- Contribution: 85.4% of total revenue
- Strategic Position: Remains cornerstone of integrated service offering
Testing Business (Steady Expansion)
- Revenue: RMB 1.13 billion (USD 165 million)
- YoY Growth: +27.4%
- Drug Safety Evaluation Subsegment: +34.8% YoY growth
- Market Leadership: Maintains industry-leading position in Asia-Pacific region
Biology Business (Solid Foundation)
- Revenue: RMB 670 million (USD 98 million)
- YoY Growth: +10.1%
- Role: Supports integrated drug discovery and development services
Operational & Strategic Highlights
- Integrated Platform Strength: Continued demand for WuXi AppTec’s comprehensive “CRDMO” (Contract Research, Development and Manufacturing Organization) model
- Backlog Visibility: RMB 59.77 billion backlog provides strong revenue visibility into future quarters
- Geographic Diversification: Global client base spanning North America, Europe, and Asia-Pacific regions
- Capacity Utilization: High utilization rates across chemistry and testing platforms driving operational leverage
Market Context & Industry Dynamics
- Pharma R&D Outsourcing: Sustained trend toward externalization of drug discovery and development activities
- China CRO Leadership: WuXi AppTec maintains dominant position in Chinese CRO market with global competitiveness
- Integrated Services Premium: Companies offering end-to-end capabilities command higher margins and client retention
- Regulatory Environment: Favorable regulatory developments in China supporting biopharmaceutical innovation
Forward-Looking Indicators
The substantial backlog growth of 23.6% year-over-year indicates strong underlying demand for WuXi AppTec’s services despite potential macroeconomic headwinds. The exceptional performance of the Chemistry segment (+43.7% YoY) demonstrates the company’s ability to capture market share in high-demand synthesis and manufacturing services.
The Drug Safety Evaluation business’s 34.8% growth within the Testing segment highlights WuXi AppTec’s leadership in preclinical safety assessment, a critical bottleneck in drug development pipelines globally.
Forward-Looking Statements
This brief contains forward-looking statements regarding financial performance, market conditions, and strategic outlook. Actual results may differ due to risks including regulatory changes, competitive dynamics, and global economic conditions.-Fineline Info & Tech